Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.24 +6.9% TUNG 1.72 +1.8% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.26 −2.6% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.51 −1.4% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.24 +6.9% TUNG 1.72 +1.8% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.26 −2.6% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.51 −1.4%
M&A / Property Neutral

Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare

Splash's $300K strategic bet validates Avicanna's pivot, but liquidity and dilution overhangs keep the stock in a holding pattern.

By The Northwire Desk — AI Analysis Jun 15, 2026 · 08:30 AVCN · 0.125 AVICANNA INC. J
Executive Summary
  • Splash Beverage Group completed a CDN$300,000 strategic investment in Avicanna Inc.
  • The transaction involves acquiring 2,000,000 common shares and 1,000,000 warrants through a non-brokered private placement.
  • Completion occurred on June 9, 2026.
  • Strategic rationale centers on Splash's transformation into a cannabinoid healthcare platform, leveraging Avicanna's clinical-stage assets, Trunerox epilepsy portfolio, MyMedi.ca platform, and Colombian manufacturing.
  • Financial impact on Avicanna is immaterial; the investment serves as a strategic validation rather than a capital infusion.
Material Impact
  • The Splash Beverage Group investment is a strategic validation but is financially immaterial ($300k). The stock's -14% decline into the print demonstrates that the market is focused on liquidity and cash burn rather than partnership announcements. The news does not change the capital structure, revenue trajectory, or clinical timeline. It is a Routine - Neutral event that reinforces the company's strategic direction without altering the near-term risk/reward profile.
AVCN · Price
Company Overview
  • Avicanna Inc. is a cannabinoid biopharmaceutical company focused on medical cannabis, clinical development, and proprietary drug delivery technologies. The company operates the MyMedi.ca medical cannabis care platform, holds the Trunerox epilepsy drug portfolio, and runs vertically integrated manufacturing operations in Colombia via its subsidiary SMGH. It is actively pursuing U.S. market entry and international expansion.
Read the original news release →

More from AVICANNA INC. J

Jun 30, 2026 · 17:30

Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer

Management Jun 12, 2026 · 17:30

Avicanna closes $600K dilutive placement at a premium to market, but cash runway remains precarious amid persistent burn.

Financings May 14, 2026 · 07:30

Avicanna Revenue Growth Masks Profitability Regression as Liquidity Improves

Earnings May 08, 2026 · 07:30

Avicanna Announces Results of Annual General and Special Meeting

Regulatory May 01, 2026 · 20:46

Avicanna Announces Change in Board of Directors

Management Apr 28, 2026 · 07:28

U.S. Rescheduling Confirmed, but Liquidity Overhang Caps Immediate Upside

Regulatory